---
case_id: c2i-genomics-ai-genomic-blood-cancer-detection
organisation: C2i Genomics
title: AI-Powered Genomic Blood Cancer Detection
date_created: '2026-01-29'
date_updated: '2026-01-29'
sources:
- id: S1
  title: https://premierinc.com/newsroom/premier-in-the-news/c2i-genomics-and-premier-tea...
  url: https://premierinc.com/newsroom/premier-in-the-news/c2i-genomics-and-premier-team-up-to-bring-ai-powered-personalized-cancer-detection-and-treatment-monitoring-to-u-s-healthcare-providers
  raw_file: ''
  text_file: sources/text/S1.txt
  extraction_method: trafilatura
  extraction_quality: high
  is_multi_page: false
  related_urls: []
- id: S2
  title: https://www.fiercebiotech.com/medtech/c2i-genomics-lands-100m-series-b-to-scale-...
  url: https://www.fiercebiotech.com/medtech/c2i-genomics-lands-100m-series-b-to-scale-up-software-detects-tiny-traces-cancer-a-single
  raw_file: ''
  text_file: sources/text/S2.txt
  extraction_method: unknown
  extraction_quality: high
  is_multi_page: false
  related_urls: []
- id: S3
  title: https://www.genomeweb.com/business-news/c2i-genomics-teams-premier-ai-driven-min...
  url: https://www.genomeweb.com/business-news/c2i-genomics-teams-premier-ai-driven-minimal-residual-disease-detection
  raw_file: ''
  text_file: sources/text/S3.txt
  extraction_method: unknown
  extraction_quality: high
  is_multi_page: false
  related_urls: []
- id: S4
  title: https://cancerletter.com/free/20230811_10e/
  url: https://cancerletter.com/free/20230811_10e/
  raw_file: ''
  text_file: sources/text/S4.txt
  extraction_method: trafilatura
  extraction_quality: high
  is_multi_page: false
  related_urls: []
- id: S5
  title: https://twistbiosciences.gcs-web.com/news-releases/news-release-details/c2i-geno...
  url: https://twistbiosciences.gcs-web.com/news-releases/news-release-details/c2i-genomics-partners-twist-bioscience-launch-reference
  raw_file: ''
  text_file: sources/text/S5.txt
  extraction_method: trafilatura
  extraction_quality: high
  is_multi_page: false
  related_urls: []
value_claims:
- id: VC-001
  claim_title: 100x more sensitive cancer detection than competing technologies
  claim_description: C2i's AI-powered whole-genome sequencing platform detects trace
    amounts of cancer at far lower levels than competing liquid biopsy technologies,
    enabling earlier detection of persistent or recurrent cancer.
  source_ids:
  - S1
  - S5
  source_quote: C2i's cancer intelligence technology works by applying whole-genome
    sequencing and artificial intelligence to just a 2ml blood sample to provide up
    to 100x more sensitive cancer detection than competing technologies.
  quote_location: S1, paragraph 5
  ai_attribution: direct
  attribution_evidence: 'AI is explicitly stated as core to the detection mechanism:
    ''applying whole-genome sequencing and artificial intelligence'' and ''uses AI
    to identify variants across the entire genome'''
  verification_status: verified
  evidence_level: method
  evidence_grade: primary
  application_type: capability_creation
  mechanism:
  - innovation
  - augmentation
  outcome:
  - experience
  - risk_avoidance
  cognitive_depth: predictive
  metric_raw:
    value: '100'
    currency: null
    magnitude: null
    timeframe: null
    metric_type: ratio
  metric_classification: null
  ontology_version: '1.0'
  ontology_confidence: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: VC-002
  claim_title: Eliminates need for patient-specific assay development
  claim_description: AI-powered technology enables personalized cancer monitoring
    without developing patient-specific assays, reducing logistics complexity and
    enabling rapid turnaround for treatment decisions.
  source_ids:
  - S1
  source_quote: This technology also eliminates the need to develop a patient-specific
    assay, enabling high performance and personalized monitoring with reduced logistic
    and rapid turnaround.
  quote_location: S1, paragraph 5
  ai_attribution: direct
  attribution_evidence: The AI-driven pattern recognition and whole-genome sequencing
    approach directly enables the elimination of patient-specific assay development,
    as stated in the technology description.
  verification_status: verified
  evidence_level: method
  evidence_grade: primary
  application_type: capability_creation
  mechanism:
  - automation
  - optimization
  outcome:
  - velocity
  - cost_reduction
  cognitive_depth: prescriptive
  metric_raw: null
  metric_classification: null
  ontology_version: '1.0'
  ontology_confidence: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: VC-003
  claim_title: Earlier stage cancer detection in blood samples
  claim_description: AI-driven pattern recognition detects traces of cancer in patient
    blood samples at earlier stages compared to currently available technologies,
    enabling better treatment decisions.
  source_ids:
  - S4
  source_quote: C2inform uses whole genome sequencing to identify cancer-related mutations
    by employing AI-driven pattern recognition to detect traces of cancer in patient
    blood samples at earlier stages compared to currently available technologies.
  quote_location: S4, paragraph 2
  ai_attribution: direct
  attribution_evidence: AI-driven pattern recognition is explicitly stated as the
    mechanism enabling earlier stage detection compared to existing technologies.
  verification_status: verified
  evidence_level: method
  evidence_grade: primary
  application_type: capability_creation
  mechanism:
  - innovation
  outcome:
  - experience
  - risk_avoidance
  cognitive_depth: predictive
  metric_raw: null
  metric_classification: null
  ontology_version: '1.0'
  ontology_confidence: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: VC-004
  claim_title: Nationwide healthcare system integration in Israel
  claim_description: C2i's AI-powered whole-genome MRD test integrated into Israel's
    nationwide healthcare system, making precision oncology testing accessible to
    entire population of nearly 10 million people.
  source_ids:
  - S4
  source_quote: Through the partnership, C2i Genomics's and its whole-genome-based
    assay will be integrated into a nationwide healthcare system for the first time.
    With Ichilov Hospital Labs serving as the reference lab for cancer hospitals across
    Israel, C2inform tests will become accessible to the entire population of Israel,
    accounting for nearly 10 million people.
  quote_location: S4, paragraph 3
  ai_attribution: direct
  attribution_evidence: The AI-powered C2inform test is the product being deployed
    at scale, with AI being core to its cancer detection capability as described in
    earlier paragraphs.
  verification_status: verified
  evidence_level: adoption
  evidence_grade: primary
  application_type: capability_creation
  mechanism:
  - innovation
  outcome:
  - business_growth
  - experience
  cognitive_depth: predictive
  metric_raw:
    value: '10000000'
    currency: null
    magnitude: null
    timeframe: null
    metric_type: count
  metric_classification: null
  ontology_version: '1.0'
  ontology_confidence: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
context_claims:
- id: CC-001
  context_type: organisational
  claim_title: C2i Genomics is a cancer intelligence company founded in 2019
  claim_description: C2i Genomics is a cancer intelligence company with headquarters
    in NYC and CLIA lab, focused on AI-powered cancer detection and monitoring.
  source_ids:
  - S1
  - S5
  source_quote: C2i Genomics, a cancer intelligence company, today announced it has
    signed a three-part collaboration agreement with Premier Inc.
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-002
  context_type: organisational
  claim_title: Premier Inc. is a technology-driven healthcare improvement company
  claim_description: Premier Inc. is a leading technology-driven healthcare improvement
    company serving hospitals, health systems and providers across the United States
    with integrated data and analytics.
  source_ids:
  - S1
  source_quote: Premier Inc., a leading technology-driven healthcare improvement company
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-003
  context_type: sectoral
  claim_title: Healthcare and precision oncology sector
  claim_description: The collaboration operates in the healthcare sector, specifically
    focused on precision oncology, cancer detection, and treatment monitoring.
  source_ids:
  - S1
  - S4
  source_quote: C2i Genomics and Premier Inc. Team Up to Bring AI-Powered Personalized
    Cancer Detection and Treatment Monitoring to U.S. Healthcare Providers
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-004
  context_type: products_services
  claim_title: C2-Intelligence Platform for cancer diagnostics
  claim_description: The C2-Intelligence Platform is a cancer diagnostics service
    that monitors disease progression and detects trace amounts of persistent or recurrent
    cancer to inform treatment decisions.
  source_ids:
  - S1
  source_quote: C2i Genomics will seek to engage Premier members in a research study
    relating to the use of the C2-Intelligence Platform, a cancer diagnostics service
    that monitors the patient's disease progression and detects trace amounts of persistent
    or recurrent cancer much earlier, at far lower levels, to inform better treatment
    decisions and improve outcomes.
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-005
  context_type: products_services
  claim_title: C2inform whole genome minimal residual disease test
  claim_description: C2inform is C2i Genomics's whole genome minimal residual disease
    (MRD) test that uses whole genome sequencing and AI-driven pattern recognition
    for cancer detection and monitoring.
  source_ids:
  - S4
  source_quote: C2i Genomics entered into a strategic collaboration to provide precision
    oncology clinical testing using C2inform, C2i Genomics's whole genome minimal
    residual disease test to improve cancer detection and monitoring nationwide.
  verification_status: unverified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-006
  context_type: scale
  claim_title: Premier Healthcare Database covers over one billion encounters
  claim_description: The Premier Healthcare Database is nationally representative
    and offers insights on more than one billion individual inpatient and outpatient
    encounters.
  source_ids:
  - S1
  source_quote: The Premier Healthcare Database (PHD) is nationally representative
    and offers insights on more than one billion individual inpatient and outpatient
    encounters.
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-007
  context_type: strategic_intent
  claim_title: Real-world evidence council and best practices development
  claim_description: The collaboration establishes a real-world evidence council and
    potential white paper development addressing best practices in point-of-care cancer
    detection solutions.
  source_ids:
  - S1
  source_quote: Initially, this collaboration will establish a real-world evidence
    council and the potential development of a white paper that addresses best practices
    in point-of-care solutions.
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-008
  context_type: functional
  claim_title: Clinical research and diagnostics function
  claim_description: The collaboration involves clinical research studies and diagnostic
    testing for minimal residual disease monitoring in cancer patients.
  source_ids:
  - S1
  - S4
  source_quote: C2i Genomics will seek to engage Premier members in a research study
    relating to the use of the C2-Intelligence Platform
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: '11.0'
  apqc_name: Develop and Manage Products and Services
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-009
  context_type: temporal
  claim_title: Partnership announced in 2023
  claim_description: The C2i Genomics and Premier Inc. collaboration was announced
    in 2023, with the Israel healthcare system partnership also occurring around the
    same timeframe.
  source_ids:
  - S1
  - S4
  source_quote: null
  verification_status: inferred
  verification_confidence: medium
  inferred_from: Source URLs and publication context suggest 2023 timeframe for these
    announcements
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
- id: CC-010
  context_type: organisational
  claim_title: Tel Aviv Sourasky Medical Center (Ichilov) partnership
  claim_description: C2i Genomics partnered with Tel Aviv Sourasky Medical Center
    (Ichilov Hospital) to serve as reference lab for cancer hospitals across Israel.
  source_ids:
  - S4
  source_quote: C2i Genomics and the Tel Aviv Sourasky Medical Center (Ichilov) entered
    into a strategic collaboration to provide precision oncology clinical testing
  verification_status: verified
  verification_confidence: high
  inferred_from: null
  apqc_code: null
  apqc_name: null
  human_validation:
    reviewed: false
    reviewer_verdict: null
    attribution_correct: null
    attribution_override: null
    missed_claim: false
    review_notes: null
    review_date: null
    reviewer_id: null
verification_summary:
  value_claims:
    total: 4
    verified: 4
    needs_review: 0
    rejected: 0
    by_attribution:
      direct: 4
  context_claims:
    total: 10
    verified: 8
    unverified: 1
    inferred: 1
  all_value_verified: true
  all_context_verified: false
human_validation_summary: null
status: complete
confidence: high
review_flags: []
ontology_metadata:
  version_used: '1.0'
  tagged_date: '2026-01-29'
  needs_retagging: false
---

# AI-Powered Genomic Blood Cancer Detection

## Executive Summary

C2i Genomics: 100x more sensitive cancer detection than competing technologies.

## Key Findings

- **100x more sensitive cancer detection than competing technologies** — verified (method)
  - Quote: "C2i's cancer intelligence technology works by applying whole-genome sequencing and artificial intelligence to just a 2ml blood sample to provide up to 100x more sensitive cancer detection than competi..."

- **Eliminates need for patient-specific assay development** — verified (method)
  - Quote: "This technology also eliminates the need to develop a patient-specific assay, enabling high performance and personalized monitoring with reduced logistic and rapid turnaround."

- **Earlier stage cancer detection in blood samples** — verified (method)
  - Quote: "C2inform uses whole genome sequencing to identify cancer-related mutations by employing AI-driven pattern recognition to detect traces of cancer in patient blood samples at earlier stages compared to ..."

- **Nationwide healthcare system integration in Israel** — verified (adoption)
  - Quote: "Through the partnership, C2i Genomics's and its whole-genome-based assay will be integrated into a nationwide healthcare system for the first time. With Ichilov Hospital Labs serving as the reference ..."

## Sources

- **S1**: https://premierinc.com/newsroom/premier-in-the-news/c2i-genomics-and-premier-team-up-to-bring-ai-powered-personalized-cancer-detection-and-treatment-monitoring-to-u-s-healthcare-providers
- **S2**: https://www.fiercebiotech.com/medtech/c2i-genomics-lands-100m-series-b-to-scale-up-software-detects-tiny-traces-cancer-a-single
- **S3**: https://www.genomeweb.com/business-news/c2i-genomics-teams-premier-ai-driven-minimal-residual-disease-detection
- **S4**: https://cancerletter.com/free/20230811_10e/
- **S5**: https://twistbiosciences.gcs-web.com/news-releases/news-release-details/c2i-genomics-partners-twist-bioscience-launch-reference
